- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT03640702
The Effect of Primary Cesarean Section Prevention on Maternal and Neonatal Outcomes
The study aimed to examine the effect of prolonging the second stage of labor on the rate of Cesarean section (CS), maternal and neonatal outcomes.
The study compared 2 time periods. The first time period was between May 2011 until April 2014 when a prolonged second stage in nulliparous women was considered three hours with regional anesthesia or two hours if no such anesthesia was provided. Second stage arrest was defined in multiparous women after two hours with regional anesthesia or one hour without it. The second time period was between May 2014 until April 2017, allowed nulliparous and multiparous women to continue the second stage of labor an additional one hour before diagnosing second-stage arrest. Singleton deliveries at or beyond 37 weeks' gestation were initially considered for eligibility.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
The study aimed to examine the effect of prolonging the second stage of labor on the rate of Cesarean section (CS), maternal and neonatal outcomes.
The study compared 2 time periods. The first time period was between May 2011 until April 2014 when a prolonged second stage in nulliparous women was considered three hours with regional anesthesia or two hours if no such anesthesia was provided. Second stage arrest was defined in multiparous women after two hours with regional anesthesia or one hour without it. The second time period was between May 2014 until April 2017, allowed nulliparous and multiparous women to continue the second stage of labor an additional one hour before diagnosing second-stage arrest. Singleton deliveries at or beyond 37 weeks' gestation were initially considered for eligibility.
The rate of CS, operative vaginal deliveries, 3rd and 4th degree lacerations, postpartum hemorrhage, arterial cord PH below 7 and admissions to the neonatal intensive care unit (NICU).
Studietyp
Inskrivning (Faktisk)
Kontakter och platser
Studieorter
-
-
-
Haifa, Israel
- Rambam Health Care Campus
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
- Barn
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Beskrivning
Inclusion Criteria:
1. Singleton deliveries at or beyond 37 weeks' gestation.
Exclusion Criteria:
- Non-vertex presentation.
- Trial of labor after CS.
- High risk pregnancy (multiple gestation, preeclampsia, diabetes mellitus, intrauterine growth restriction).
- Known fetal anomalies and intrauterine fetal demise.
Studieplan
Hur är studien utformad?
Designdetaljer
Kohorter och interventioner
Grupp / Kohort |
Intervention / Behandling |
|---|---|
|
Prolonged second stage of labor
Women with prolonged second stage of labor as specified before.
|
To examine the effect of prolonging the second stage of labor on the rate of cesarean delivery, maternal and neonatal outcomes
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
The rate of primary CS.
Tidsram: Between 2011 and 2017.
|
The rate of primary CS in percentage of the total participants.
|
Between 2011 and 2017.
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
The rate of operative vaginal delivery.
Tidsram: Between 2011 and 2017.
|
The rate of operative vaginal delivery in percentage of the total participants.
|
Between 2011 and 2017.
|
|
Post-partum hemorrhage.
Tidsram: Between 2011 and 2017.
|
Post-partum hemorrhage as estimated in liters.
|
Between 2011 and 2017.
|
|
The need for blood transfusion.
Tidsram: Between 2011 and 2017.
|
Number and type of blood products required post-partum and calculation of the number of patients that required blood products out of the total number of participants in percentage.
|
Between 2011 and 2017.
|
|
Third-and fourth-degree laceration rate.
Tidsram: Between 2011 and 2017.
|
Third-and fourth-degree laceration rate of the total number of participants.
|
Between 2011 and 2017.
|
|
Chorioamnionitis rate.
Tidsram: Between 2011 and 2017.
|
Chorioamnionitis rate in percentage of the total participants.
|
Between 2011 and 2017.
|
|
Admission to the NICU.
Tidsram: Between 2011 and 2017.
|
Admission to the NICU in percentage of the total participants.
|
Between 2011 and 2017.
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Kamel Mattar, MD, Principal Investigator
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Andra studie-ID-nummer
- 0258-17-RMB
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .